Literature DB >> 24905393

Subacute posttraumatic ascending myelopathy in a 15-year-old boy.

Timothy J Kovanda1, Eric M Horn.   

Abstract

Secondary injury following initial spinal cord trauma is uncommon and frequently attributed to mismanagement of an unprotected cord in the acute time period after injury. Subacute posttraumatic ascending myelopathy (SPAM) is a rare occurrence in the days to weeks following an initial spinal cord injury that is unrelated to manipulation of an unprotected cord and involves 4 or more vertebral levels above the original injury. The authors present a case of SPAM occurring in a 15-year-old boy who sustained a T3-4 fracture-dislocation resulting in a complete spinal cord injury, and they highlight the imaging findings and optimum treatment for this rare event.

Entities:  

Keywords:  SPAM = subacute posttraumatic ascending myelopathy; secondary spinal cord injury; subacute posttraumatic ascending myelopathy; trauma; traumatic spinal cord injury

Mesh:

Year:  2014        PMID: 24905393     DOI: 10.3171/2014.5.SPINE13754

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  4 in total

1.  Subacute posttraumatic ascending myelopathy (SPAM): A potential complication of subarachnoid shunt for syringomyelia?

Authors:  Vincenzo Levi; Andrea Franzini; Andrea Di Cristofori; Giulio Bertani; Mauro Pluderi
Journal:  J Spinal Cord Med       Date:  2018-08-29       Impact factor: 1.985

2.  Subacute post-traumatic ascending myelopathy after T12 burst fracture in a 32-year-old male: case report and surgical result of cervical durotomy.

Authors:  Jian Zhang; Huili Wang; Haiying Liu; Guangshun Wang
Journal:  Spinal Cord Ser Cases       Date:  2016-07-07

Review 3.  Subacute posttraumatic ascending myelopathy: a literature review.

Authors:  J Zhang; G Wang
Journal:  Spinal Cord       Date:  2016-12-20       Impact factor: 2.772

4.  Posttraumatic ascending myelopathy after spinal cord injury in a young man: A case report.

Authors:  Mostafa Esmaeilnia; Mona Asadi; Hussein Sharara
Journal:  Clin Case Rep       Date:  2022-08-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.